An experimental vaccine that stimulates immune responses against three regions of the alpha-synuclein protein — whose toxic clumps contribute to Parkinson’s disease and dementia with Lewy bodies (DLB) — is moving into late-stage preclinical research aimed at supporting future requests to test it in clinical trials. Called PV-1950R,…
News
The Parkinson’s Foundation and data analytics company Tag.bio are partnering to help advance Parkinson’s disease research, with the goal being better treatments and improved care. “We are thrilled to partner with the Parkinson’s Foundation, a global leader in improving life for those living with Parkinson’s disease,” said…
Changes in the structure of 76 proteins in the cerebrospinal fluid (CSF) of people with Parkinson’s disease were seen when compared with those of healthy individuals, a study reported. Its researchers believe their work is the first to look at protein structure — rather than abundance — to identify potential…
New machine learning models based on walking patterns accurately distinguished between Parkinson’s patients and healthy people, and between different stages of the disease, a study showed. “We chose gait parameters as the key criteria because gait impairments appear early in Parkinson’s and get worse over time, and also because…
A machine-learning tool that combines genetic and clinical data can distinguish, with a high level of accuracy, between fast- and slow-progressing Parkinson’s patients, a study reported. The tool could be used to predict those patients who are more likely to progress over the short term — and who could…
Krill oil, which comes from a shrimp-like animal, protected dopamine-producing neurons from age-related degeneration and boosted neurologic processes dependent on the brain chemical messenger in a worm model of Parkinson’s disease, a study showed. The production of dopamine is gradually impaired in people with Parkinson’s due to the progressive…
ABBV-951, a continuous infusion formulation of levodopa/carbidopa that’s administered under the skin, improved “on” time and decreased “off” time when compared with standard oral therapy in people with advanced Parkinson’s disease. Those are the results of a randomized Phase 3 clinical trial testing the experimental formulation in more than…
Exposure to airborne pollutants, which is rising as a result of climate change, appears to increase the risk of Parkinson’s disease, according to a review study into how a changing environment can affect human health. Air pollutants and other aspects of climate change also were found to associate with…
Metabolon is teaming up with Tracking Parkinson’s, the world’s largest long-term study into Parkinson’s disease, to identify novel metabolic biomarkers of disease progression. The discoveries may lead to personalized treatments and better patient care. “We are extremely enthusiastic about partnering with Tracking Parkinson’s to further the understanding…
The small molecule anle138b, an experimental therapy for Parkinson’s disease, was shown in a study to bind to lipidic (fat) fibrils in alpha-synuclein protein clumps, suggesting it could also offer a new diagnostic approach for the disease. “The promising drug candidate anle138b … binds to lipidic alpha-synuclein structures. The drug…
Recent Posts
- New report shows Parkinson’s costs surpass $82 billion in US in 2024
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China
- Fecal transplants ease motor symptoms in early Parkinson’s: Study
- ‘Moving Day, A Walk for Parkinson’s’ marks 15th year with events across US